scholarly journals Association Between Depressive Symptoms and Incidence of Crohn's Disease and Ulcerative Colitis: Results From the Nurses' Health Study

2013 ◽  
Vol 11 (1) ◽  
pp. 57-62 ◽  
Author(s):  
Ashwin N. Ananthakrishnan ◽  
Hamed Khalili ◽  
An Pan ◽  
Leslie M. Higuchi ◽  
Punyanganie de Silva ◽  
...  
Author(s):  
Inês A Trindade ◽  
Nuno B Ferreira

Abstract Aims No empirical research on the psychological impact of the coronavirus disease 2019 (COVID-19) pandemic on people living with IBD, a population known to typically present high levels of anxiety and depression and to be potentially vulnerable to COVID-19, has yet been conducted. This study aimed to explore the links between contextual variables related to the COVID-19 pandemic and disease and psychological outcomes. Methods The sample included 124 Portuguese patients with Crohn’s disease or ulcerative colitis (85.48% women) who completed self-reported measures in an online survey during April 2020. Results Fear of contracting COVID-19 and medication adherence were both high and unrelated. About half of the sample presented moderate (37.10%) to severe (14.50%) anxiety. Normal and mild anxiety levels were at 29.80% and 18.50%, respectively. Regarding depressive symptoms, 51.60% of the sample presented normal levels, 27.40% mild severity, 16.10% moderate, and 4.8% severe. No differences were found between Crohn’s disease and ulcerative colitis patients. Regression analyses showed that anxiety explained IBD symptom perception (β = 0.29; P = 0.022); fear of contracting COVID-19 (β = 0.35; P < 0.001) and IBD symptom perception (β = −0.22; P = 0.009) explained depressive symptoms; and fear of contracting COVID-19 (β = 0.41; P < 0.001), IBD symptom perception (β = 0.26, P < 0.001), and being in isolation (β = −0.16, P = 0.041) explained anxiety. Type of medication was not linked to these outcomes. Conclusions The COVID-19 pandemic does not seem to be affecting adherence to medication but seems to present relevant effects on psychological well-being. Inflammatory bowel disease health care professionals should be attentive of patients’ psychological response to this pandemic and of its possible consequences on disease expression. This study additionally provided a psychometrically sound measure of fear of contracting COVID-19.


2012 ◽  
Vol 142 (5) ◽  
pp. S-88 ◽  
Author(s):  
Ashwin N. Ananthakrishnan ◽  
Hamed Khalili ◽  
An Pan ◽  
Leslie M. Higuchi ◽  
Punyanganie S. de Silva ◽  
...  

2021 ◽  
Vol 5 (Supplement_2) ◽  
pp. 462-462
Author(s):  
Fenglei Wang ◽  
Megu Baden ◽  
Yanping Li ◽  
Frank Hu ◽  
Walter Willett ◽  
...  

Abstract Objectives Several plant-based foods have been associated with a lower risk of Crohn's disease (CD) and ulcerative colitis (UC), but not all plant-based foods are healthy. We aimed to examine the association of various plant-based diets with the risk of CD and UC. Methods We followed 169 945 women in the Nurses’ Health Study and Nurses’ Health Study II for up to 32 years. Plant-based diets were assessed by three indices derived from the food frequency questionnaires: an overall plant-based diet index (PDI), a healthful plant-based diet index (hPDI), and an unhealthful plant-based diet index (uPDI). Self-reported CD and UC were confirmed through medical record review. Results We documented 320 incident CD cases and 404 incident UC cases during 4 317 561 person-years. A higher hPDI was associated with a lower risk of UC (hazard ratio [HR] comparing extreme quintiles: 0.67; 95% confidence interval [CI]: 0.47–0.94; P-trend = 0.02). In contrast, the uPDI was associated with an increased risk of CD (HR: 1.67; 95% CI: 1.11–2.51; P-trend = 0.002) and UC (HR: 1.65; 95% CI: 1.15–2.35; P-trend = 0.03). Replacing refined grains, sugar-sweetened beverages, and sweets/desserts with an equal serving of fruits or vegetables was associated with lower risk of CD and UC. Conclusions A healthful plant-based diet rich in fruits and vegetables was associated with a lower UC risk, whereas a plant-based diet emphasizing less healthy plant foods such as refined grains, sugar-sweetened beverages, and sweets/desserts was associated with a higher CD and UC risk. Funding Sources National Institutes of Health.


2001 ◽  
Vol 120 (5) ◽  
pp. A459-A459
Author(s):  
A RECTOR ◽  
P LEMEY ◽  
W LAFFUT ◽  
E KEYAERTS ◽  
F STRUYF ◽  
...  

2008 ◽  
Vol 46 (05) ◽  
Author(s):  
Z Szepes ◽  
K Farkas ◽  
T Molnar ◽  
F Nagy ◽  
T Nyari ◽  
...  

2020 ◽  
Vol 15 (3) ◽  
pp. 216-233 ◽  
Author(s):  
Maliha Naseer ◽  
Shiva Poola ◽  
Syed Ali ◽  
Sami Samiullah ◽  
Veysel Tahan

The incidence, prevalence, and cost of care associated with diagnosis and management of inflammatory bowel disease are on the rise. The role of gut microbiota in the causation of Crohn's disease and ulcerative colitis has not been established yet. Nevertheless, several animal models and human studies point towards the association. Targeting intestinal dysbiosis for remission induction, maintenance, and relapse prevention is an attractive treatment approach with minimal adverse effects. However, the data is still conflicting. The purpose of this article is to provide the most comprehensive and updated review on the utility of prebiotics and probiotics in the management of active Crohn’s disease and ulcerative colitis/pouchitis and their role in the remission induction, maintenance, and relapse prevention. A thorough literature review was performed on PubMed, Ovid Medline, and EMBASE using the terms “prebiotics AND ulcerative colitis”, “probiotics AND ulcerative colitis”, “prebiotics AND Crohn's disease”, “probiotics AND Crohn's disease”, “probiotics AND acute pouchitis”, “probiotics AND chronic pouchitis” and “prebiotics AND pouchitis”. Observational studies and clinical trials conducted on humans and published in the English language were included. A total of 71 clinical trials evaluating the utility of prebiotics and probiotics in the management of inflammatory bowel disease were reviewed and the findings were summarized. Most of these studies on probiotics evaluated lactobacillus, De Simone Formulation or Escherichia coli Nissle 1917 and there is some evidence supporting these agents for induction and maintenance of remission in ulcerative colitis and prevention of pouchitis relapse with minimal adverse effects. The efficacy of prebiotics such as fructooligosaccharides and Plantago ovata seeds in ulcerative colitis are inconclusive and the data regarding the utility of prebiotics in pouchitis is limited. The results of the clinical trials for remission induction and maintenance in active Crohn's disease or post-operative relapse with probiotics and prebiotics are inadequate and not very convincing. Prebiotics and probiotics are safe, effective and have great therapeutic potential. However, better designed clinical trials in the multicenter setting with a large sample and long duration of intervention are needed to identify the specific strain or combination of probiotics and prebiotics which will be more beneficial and effective in patients with inflammatory bowel disease.


Sign in / Sign up

Export Citation Format

Share Document